Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $41.00 Average Price Target from Brokerages

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has earned a consensus rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $41.00.

Several equities research analysts recently commented on the company. Zacks Research lowered Lyell Immunopharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Wall Street Zen lowered Lyell Immunopharma from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Citizens Jmp assumed coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price on the stock. Needham & Company LLC assumed coverage on Lyell Immunopharma in a research report on Friday. They set a “buy” rating and a $44.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $22.39 on Friday. The business’s 50-day moving average price is $22.62 and its two-hundred day moving average price is $22.78. Lyell Immunopharma has a 12 month low of $7.65 and a 12 month high of $45.00. The firm has a market capitalization of $522.36 million, a PE ratio of -1.37 and a beta of -0.06.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Thursday, March 12th. The company reported ($7.68) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($5.53). Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.02 million. As a group, analysts forecast that Lyell Immunopharma will post -0.78 earnings per share for the current fiscal year.

Insider Activity at Lyell Immunopharma

In related news, insider Gary K. Lee sold 1,671 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $39,084.69. Following the sale, the insider owned 16,938 shares in the company, valued at $396,179.82. This represents a 8.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Stephen J. Hill sold 1,236 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $28,910.04. Following the completion of the transaction, the chief operating officer owned 17,795 shares in the company, valued at approximately $416,225.05. The trade was a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,310 shares of company stock worth $264,285 in the last 90 days. Corporate insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after acquiring an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new position in Lyell Immunopharma in the second quarter worth approximately $94,000. Bridgeway Capital Management LLC bought a new position in Lyell Immunopharma in the second quarter worth approximately $159,000. BBR Partners LLC bought a new position in Lyell Immunopharma in the fourth quarter worth approximately $210,000. Finally, Walleye Capital LLC bought a new position in Lyell Immunopharma in the second quarter worth approximately $258,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.